Cargando…

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested. METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/or chromosome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schleiermacher, G, Mosseri, V, London, W B, Maris, J M, Brodeur, G M, Attiyeh, E, Haber, M, Khan, J, Nakagawara, A, Speleman, F, Noguera, R, Tonini, G P, Fischer, M, Ambros, I, Monclair, T, Matthay, K K, Ambros, P, Cohn, S L, Pearson, A D J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494425/ https://www.ncbi.nlm.nih.gov/pubmed/22976801 http://dx.doi.org/10.1038/bjc.2012.375

Ejemplares similares

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
por: Ambros, P F, et al.
Publicado: (2009)

Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
por: Matthay, K K, et al.
Publicado: (2010)

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients
por: Depuydt, Pauline, et al.
Publicado: (2018)

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
por: Ambros, Inge M., et al.
Publicado: (2020)

Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG) †
por: Ohira, Miki, et al.
Publicado: (2021)

Identification of the Novel Methylated Genes' Signature to Predict Prognosis in INRG High-Risk Neuroblastomas
por: Liu, Zhichao, et al.
Publicado: (2021)

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
por: Schleiermacher, G, et al.
Publicado: (2011)

Retracted: Identification of the Novel Methylated Genes' Signature to Predict Prognosis in INRG High-Risk Neuroblastomas
por: Osteoporosis, Journal of
Publicado: (2022)

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
por: De Bernardi, B, et al.
Publicado: (2008)

Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics
por: Ambros, Inge M., et al.
Publicado: (2014)

Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months
por: Fischer, Janina, et al.
Publicado: (2017)

Bone marrows from neuroblastoma patients: An excellent source for tumor genome analyses
por: Abbasi, M. Reza, et al.
Publicado: (2014)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors
por: Brunner, Clemens, et al.
Publicado: (2016)

Modulation of multidrug resistance proteins by statins in human neuroblastoma
por: Sieczkowski, Evelyn, et al.
Publicado: (2008)

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
por: Defferrari, R, et al.
Publicado: (2015)

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group
por: DuBois, Steven G., et al.
Publicado: (2012)

Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression
por: Rifatbegovic, Fikret, et al.
Publicado: (2017)

In vitro and in vivo profiling of P-glycoprotein in human neuroblastoma and rhabdomyosarcoma cells under simvastatin exposure
por: Sieczkowski, Evelyn, et al.
Publicado: (2009)

A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma
por: Gamble, Laura D., et al.
Publicado: (2021)

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma
por: Schriegel, Felix, et al.
Publicado: (2021)

Meta-mining of copy number profiles of high-risk neuroblastoma tumors
por: Depuydt, Pauline, et al.
Publicado: (2018)

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
por: Martinez-Monleon, Angela, et al.
Publicado: (2022)

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force
por: Beiske, K, et al.
Publicado: (2009)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging
por: Lazic, Daria, et al.
Publicado: (2021)

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification
por: Schleiermacher, G, et al.
Publicado: (2007)

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial
por: de Alarcon, Pedro A., et al.
Publicado: (2017)

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
por: Chand, Damini, et al.
Publicado: (2013)

Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma.
por: Meltzer, S. J., et al.
Publicado: (1996)

Identification of CASZ1 nuclear export signal (NES) reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma
por: Liu, Zhihui, et al.
Publicado: (2016)

Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival
por: Brisse, Hervé J., et al.
Publicado: (2017)

Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
por: Matthay, K K, et al.
Publicado: (2000)

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism
por: Mandriota, Stefano J., et al.
Publicado: (2015)

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
por: Decock, Anneleen, et al.
Publicado: (2015)

Treatment of stage 4s neuroblastoma – report of 10 years' experience of the French Society of Paediatric Oncology (SFOP)
por: Schleiermacher, G, et al.
Publicado: (2003)

Impulsschaltungen, Erzeugung und Verarbeitung von Impulsen mit Röhren und Transistoren
por: Speiser, Ambros P
Publicado: (1963)

Neuroblastoma by chance
por: Tonini, Gian Paolo
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rt8j5r7cfamat9e76essm0hb93